evipedia.ai
← Back

Oleoylethanolamide for Health & Longevity

Evidence Review created on 10/15/2026 using AI4L / Opus 5.5

Also known as: OEA, N-Oleoylethanolamine, Oleoyl Ethanolamide, Oleylethanolamide, RiduZone, TRPTI

Motivation

Oleoylethanolamide is a signaling molecule that the small intestine makes from oleic acid, the main fat in olive oil, after a meal. It works as one of the body’s own fullness signals, switching on a cellular sensor that tells tissues to burn fat and the brain to wait longer before the next meal. Because the body already produces it, and because it is now sold as an oral supplement, it has drawn interest from people looking for help with appetite and metabolic health.

Interest began with animal research in the early 2000s that examined its role in feeding behavior. Since then, small human trials have studied it in relation to body weight and blood sugar, and laboratory studies in worms have explored a possible connection to lifespan, which brought it to the attention of people interested in healthy aging.

This review examines the human and laboratory evidence on oleoylethanolamide supplementation: its possible benefits, its risks and unknowns, how it is dosed and monitored, and how strongly the research supports its use by health-conscious adults pursuing a longer, healthier life.

Benefits - Risks - Protocol - Conclusion

The following expert sources give a high-level overview of oleoylethanolamide’s biology, its role in appetite and metabolism, and its links to aging research.

No relevant content on oleoylethanolamide was found from Rhonda Patrick (FoundMyFitness), Peter Attia, Andrew Huberman, Chris Kresser or Lifespan.io: on-site and web searches returned no article, episode or segment discussing it. Life Extension’s site search was blocked by a security page, and web searches found no Life Extension article on it.

Grokipedia

Oleoylethanolamide

An AI-written overview of the compound’s chemistry, production in the body, receptors and preclinical and clinical findings; useful for orientation, though its claims need checking against the primary studies.

Examine

Oleoylethanolamide

Examine’s independent summary, updated August 2025, notes that rat studies consistently show reduced food intake but that human evidence for fat loss from oral supplementation remains insufficient.

ConsumerLab

No dedicated ConsumerLab article on oleoylethanolamide exists. ConsumerLab mentions it only in a June 2026 clinical update on a palmitoylethanolamide-plus-oleoylethanolamide study, filed within its palmitoylethanolamide coverage.

Systematic Reviews

The following systematic reviews and meta-analyses summarize the controlled human trials and the preclinical research on oleoylethanolamide.

No systematic review or meta-analysis has examined oleoylethanolamide’s adverse effects, so the risk side of the trade-off is unrepresented here.

Mechanism of Action

Oleoylethanolamide (OEA) is a signaling lipid made by the upper small intestine from dietary oleic acid after fatty meals, using CD36 (a cell-surface fat transporter) (Schwartz et al., 2008). Its main target is PPAR-α (peroxisome proliferator-activated receptor alpha, a gene switch that turns on fat burning), which it binds tightly; mice lacking this receptor showed no OEA effect on food intake or weight (Fu et al., 2003). PPAR-α activation boosts fat breakdown in liver, muscle and fat tissue and dampens inflammation.

OEA also activates GPR119 (a gut receptor releasing GLP-1, glucagon-like peptide-1, a fullness and insulin-releasing hormone) (Hansen et al., 2012) and TRPV1 (a sensory-nerve channel also activated by capsaicin). Its fullness signal reaches the brain via sensory nerves, raising oxytocin release in the hypothalamus (the brain’s appetite-control center) (Gaetani et al., 2010). It does not activate cannabinoid receptors, the targets of cannabis.

OEA is broken down by FAAH (fatty acid amide hydrolase, an enzyme that degrades this lipid family) and NAAA (N-acylethanolamine acid amidase, a related enzyme) (Rahman et al., 2014). Its human half-life is unreported; much of its action appears local to the gut, though supplementation raised blood OEA over 10 weeks (Abdullah et al., 2026).

Competing views: in rats, appetite loss after high injected doses coincided with reduced movement, suggesting malaise rather than true fullness (Fedele et al., 2018). In worms, OEA extended lifespan (Folick et al., 2015), yet lowering this lipid family also extended lifespan, via diet restriction (Lucanic et al., 2011).

Historical Context & Evolution

OEA was never a drug or traditional remedy; it is a natural body lipid, long regarded as a minor relative of the cannabis-like messenger anandamide. In 2001, a Madrid–Irvine team led by Fernando Rodríguez de Fonseca and Daniele Piomelli reported that fasting lowers its production in the rat gut and that injecting it reduces food intake and weight gain (Rodríguez de Fonseca et al., 2001). In 2003 the same researchers identified PPAR-α as its receptor (Fu et al., 2003), and in 2008 showed that dietary fat triggers its production (Schwartz et al., 2008).

These findings made it a candidate obesity treatment, and by the mid-2010s it was sold as a weight-management supplement. In 2015 a Baylor team reported that it extends lifespan in worms (Folick et al., 2015), drawing longevity interest. From 2018, small randomized trials, mostly from groups in Tabriz and Qazvin, Iran, tested 125–250 mg/day in obesity, fatty liver, prediabetes and other conditions; several papers report different outcomes from the same two Tabriz trials. Meta-analyses pooled these trials in 2025 (Bahari et al., 2025).

Views on mechanism have also shifted: a Zurich group found that high-dose appetite suppression in rats coincided with impaired movement (Fedele et al., 2018), reopening the question of fullness versus malaise. Since 2025, manufacturer-funded trials in Australia (Batacan et al., 2026) and a veterans’ trial in the US (Abdullah et al., 2026) have added new formulations and endpoints, with mixed results on body weight.

Expected Benefits

High 🟩 🟩 🟩

Lower Fasting Blood Glucose and Insulin Resistance ⚠️ Conflicted

OEA may aid blood sugar control through GLP-1 release and PPAR-α-driven fat burning. Two independent Iranian groups reported lower fasting glucose versus placebo: Tutunchi and Ostadrahimi in Tabriz, in obese adults with fatty liver (Tutunchi et al., 2020), and Khadem Haghighian in Qazvin, in prediabetes (Pouryousefi et al., 2022). Trials in healthy obese adults from Tabriz (Ostadrahimi et al., 2024) and Australia (Batacan et al., 2026) found no fasting-glucose change. Net reading: a modest fasting-glucose reduction is likely, mainly in people with impaired glucose control.

Magnitude: Fasting glucose 5.84 mg/dL lower than control (95% CI −10.33 to −1.35; CI, confidence interval, the range likely to contain the true effect) and fasting insulin 3.26 µU/mL lower (95% CI −6.22 to −0.31) across pooled trials (Eslahi et al., 2025).

Medium 🟩 🟩

Reduced Appetite and Food Intake ⚠️ Conflicted

OEA is one of the gut’s own fullness signals. In 60 adults with obesity, 250 mg/day for 8 weeks reduced hunger, desire to eat and sweet cravings in the supplement group (Laleh et al., 2018). A single-dose study funded by the manufacturer Gencor found less lunch eaten than after placebo, yet identical fullness ratings (Briskey et al., 2026). Net reading: modest reductions in food intake are plausible, while effects on felt appetite are inconsistent.

Magnitude: After one dose, 11.5–14.2% of a standard lunch was left uneaten versus 6.8% after placebo (fixed-order crossover, 37 adults), while pre-lunch fullness scores were 31.3–31.8 versus 31.8 on a 100 mm scale (Briskey et al., 2026).

Lower Triglycerides ⚠️ Conflicted

Through PPAR-α, the receptor also targeted by fibrates (triglyceride-lowering drugs), OEA may speed fat breakdown in the liver. Two Tabriz trials found lower triglycerides than placebo (Ostadrahimi et al., 2024; Tutunchi et al., 2020). A 12-week Australian trial funded by Gencor (Batacan et al., 2026) and a US veterans’ trial (Abdullah et al., 2026) found no triglyceride difference. Net reading: a small triglyceride reduction is supported mainly by one research group and lacks independent confirmation.

Magnitude: Triglycerides 17.73 mg/dL lower than control (95% CI −31.86 to −3.79) across pooled trials (Eslahi et al., 2025).

Less Fatigue and Better Mood

In 52 veterans with Gulf War Illness (a chronic condition of fatigue, pain and mood problems in 1990–1991 Gulf War veterans), 400 mg/day for 10 weeks reduced fatigue and improved overall mood versus placebo, with better energy and emotional well-being (Abdullah et al., 2026). Thinking and pain scores did not change. This single exploratory trial from the Roskamp Institute has not been repeated in other populations.

Magnitude: A significant group effect favored oleoylethanolamide on the Multidimensional Fatigue Inventory total score and on total mood disturbance (both p = 0.03 after correction for multiple tests; p, the probability that a difference this large arises by chance); the trial reports no between-group difference in score points (Abdullah et al., 2026).

Less Menstrual Pain

In 44 young women with primary dysmenorrhea (painful periods without underlying disease), 125 mg/day for 2 months reduced pain versus placebo, alongside lower inflammation and oxidative stress markers (Kazemi et al., 2022). A meta-analysis rated this trial at high risk of bias (Bahari et al., 2025). The finding comes from one Qazvin group and applies to premenopausal women.

Magnitude: Pain scores fell more with oleoylethanolamide than with placebo after 60 days (p = 0.040); the published abstract reports no effect size (Kazemi et al., 2022).

Low 🟩

Small Reductions in Body Weight and Fat Mass ⚠️ Conflicted

Pooled Iranian trials showed small weight, waist and fat-mass reductions, driven by two Tabriz trials (Bahari et al., 2025). Another meta-analysis (Eslahi et al., 2025) and two newer trials (Batacan et al., 2026; Abdullah et al., 2026) found no weight effect. Net reading: any effect is small and unconfirmed.

Magnitude: Body weight standardized mean difference −0.26 (95% CI −0.51 to −0.02; standardized mean difference, an effect size in standard-deviation units where 0.2 is small) across 4 trials (Bahari et al., 2025); pooled weight change −2.15 kg (95% CI −3.25 to 0.96), not significant (Eslahi et al., 2025).

Improved Cholesterol Ratios ⚠️ Conflicted

In fatty-liver patients, OEA lowered ratios of LDL (“bad” cholesterol) and triglycerides to HDL (“good” cholesterol) versus placebo (Tutunchi et al., 2020). Pooled trials showed no change in LDL, HDL or total cholesterol (Bahari et al., 2025). Net reading: no reliable cholesterol benefit from OEA alone.

Magnitude: Pooled LDL standardized mean difference 0.25 (95% CI −0.27 to 0.78), not significant (Bahari et al., 2025).

Liver Health in Fatty Liver Disease ⚠️ Conflicted

In obese adults with new fatty liver disease on a calorie-restricted diet, 250 mg/day for 12 weeks lowered liver enzymes versus placebo, but liver fat on ultrasound did not differ between groups (Tutunchi et al., 2020). Net reading: enzyme gains are indirect markers, unmatched by a liver-fat difference.

Magnitude: Liver fat severity fell in both groups with no significant between-group difference (p = 0.061); the enzyme differences were significant, but the abstract gives no figures (Tutunchi et al., 2020).

Speculative 🟨

Lower Inflammation Markers ⚠️ Conflicted

Pooling showed lower C-reactive protein and tumor necrosis factor-alpha, both inflammation markers (Bahari et al., 2025). Two trials found no change (Tutunchi et al., 2023; Abdullah et al., 2026). Net reading: inconsistent.

Lower Oxidative Stress Markers ⚠️ Conflicted

Trials report higher total antioxidant capacity and lower malondialdehyde (a fat-damage marker) (Tutunchi et al., 2023); one meta-analysis found no pooled malondialdehyde change (Eslahi et al., 2025). Net reading: unvalidated markers with inconsistent results.

Healthier Gut Microbiome

Two independent trials found more Akkermansia muciniphila (a gut bacterium linked to metabolic health) after 8–12 weeks (Payahoo et al., 2019; Batacan et al., 2026). Microbiome shifts are not validated health outcomes.

Lifespan Extension

OEA extended lifespan in worms (Folick et al., 2015), also alongside other fasting-induced metabolites (Rhodes et al., 2023). The basis is non-human only; no mammalian lifespan data exist.

Brain Protection with Aging ⚠️ Conflicted

A stable OEA analog reduced amyloid plaque (Alzheimer’s protein clumps) and memory loss in mice (Comerota et al., 2023). In veterans, OEA left cognitive scores unchanged (Abdullah et al., 2026). Net reading: animal-only signal.

Reduced Alcohol Craving and Damage

Rodent studies show OEA reduces alcohol seeking, withdrawal and alcohol-driven brain inflammation (a review by Orio et al., 2018). Human evidence is limited to blood-level correlations.

Benefit-Modifying Factors

  • Genetic polymorphisms: Carriers of the A allele of rs324420 in the FAAH gene (which encodes the main OEA-degrading enzyme) had higher blood OEA after 30-day dietary-oil treatments (Pu et al., 2016); whether they respond differently to supplements is untested.
  • Baseline biomarkers: Pooled weight and fasting-glucose reductions were significant only in trials of people with obesity and at doses of 250 mg/day or more (Bahari et al., 2025); metabolically healthy obese adults showed no fasting-glucose change (Ostadrahimi et al., 2024).
  • Sex: Reductions in inflammation and oxidative-stress markers were significant only in female-only trials (Bahari et al., 2025); blood OEA patterns also differ by sex and menopause (Fanelli et al., 2018).
  • Pre-existing conditions: Obesity and high-fat diets blunt the gut’s own OEA production in rodents (Igarashi et al., 2015), which may make supplementation more relevant in obesity, fatty liver, prediabetes and PCOS (polycystic ovary syndrome, a hormonal disorder with insulin resistance).
  • Age: Relative blood OEA rises with age in men (Fanelli et al., 2018); trials enrolled mostly adults aged 20–65, so benefits in people over 70 are untested.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been documented in controlled trials from more than one independent research group.

Medium 🟥 🟥

No risk reaches Medium: no controlled trial has recorded any adverse event occurring more often with OEA than with placebo.

Low 🟥

Mild Digestive Upset ⚠️ Conflicted

Mild digestive complaints are the side effects most often attributed to OEA (Bahari et al., 2025). During a 10-week placebo-controlled phase, digestive events were similar with OEA and placebo (Abdullah et al., 2026). Net reading: any digestive effect is mild and not clearly above placebo.

Magnitude: During the 10-week randomized phase, 8 digestive adverse events with OEA versus 10 with placebo (26 participants per group; p > 0.05), with no serious events (Abdullah et al., 2026).

Speculative 🟨

Excess Appetite Loss in Lean or Frail Adults

By design, OEA lowers food intake; in lean, older or frail adults this could reduce protein intake and muscle. The basis is mechanistic only, as trials enrolled mainly overweight adults.

Malaise at High Doses

In rats, high injected doses reduced movement alongside eating, suggesting discomfort (Fedele et al., 2018). The basis is animal injection data, not oral human dosing.

Fibrate-Like Effects ⚠️ Conflicted

Fibrates, which also activate PPAR-α, can raise creatinine and gallstone risk; for OEA this concern is mechanistic. Creatinine did not differ from placebo over 12 weeks (Batacan et al., 2026). Net reading: no signal yet.

Blunting Diet-Restriction Longevity Effects

In worms, lowering this lipid family extended lifespan, and supplementing a related lipid blocked diet-restriction longevity (Lucanic et al., 2011). The basis is mechanistic; relevance to humans is unknown.

Risk-Modifying Factors

  • Genetic polymorphisms: No gene variant is known to change OEA’s side effects; FAAH rs324420 A-allele carriers, who maintain higher blood OEA (Pu et al., 2016), may clear it more slowly (theoretical).
  • Baseline biomarkers: People with low body weight, low muscle mass or low-normal fasting glucose have less margin for further appetite or glucose lowering.
  • Sex: No sex differences in adverse events have been reported; pregnancy has not been studied, and one trial excluded women who could become pregnant (Batacan et al., 2026).
  • Pre-existing conditions: Eating disorders, diabetes treated with glucose-lowering drugs, and kidney or gallbladder disease (given fibrate-like effects) raise theoretical risk.
  • Age: Adults over 70 are untested (the veterans’ trial enrolled up to age 70) (Abdullah et al., 2026); older adults prone to undereating or muscle loss face greater risk from appetite suppression.

Key Interactions & Contraindications

No human drug-interaction study of OEA exists, so every interaction below is inferred from mechanism.

  • Glucose-lowering drugs (metformin, glipizide, insulin, SGLT2 inhibitors such as empagliflozin, which make kidneys excrete glucose): Monitor (theoretical). Additive glucose lowering could cause hypoglycemia (low blood sugar). Trial participants taking metformin reported no side effects (Pouryousefi et al., 2022). Early, frequent glucose checks mitigate this.
  • GLP-1 receptor agonists (injected appetite-suppressing drugs that mimic the gut hormone GLP-1, such as semaglutide, tirzepatide, liraglutide): Caution (theoretical). Additive appetite suppression and digestive effects may cut protein intake and speed muscle loss; tracking intake and weight mitigates this.
  • Fibrates (fenofibrate, gemfibrozil): Caution (theoretical). Both activate PPAR-α, so lipid and kidney effects could add up; triglyceride and creatinine checks mitigate this.
  • Orlistat (over-the-counter fat blocker): Monitor (theoretical). By reducing fat absorption, it may lower the gut’s own OEA production and add digestive side effects; no mitigation beyond symptom tracking is known.
  • Ibuprofen and other over-the-counter anti-inflammatory painkillers: Monitor (theoretical). Some inhibit FAAH in laboratory studies, which could raise OEA levels; the clinical consequence is unknown.
  • Palmitoylethanolamide (PEA, a related lipid supplement): Monitor (theoretical). It shares degrading enzymes and may raise OEA exposure; a combination product containing both showed no excess adverse effects in a manufacturer-run trial (Grant et al., 2026).
  • Berberine, chromium and other glucose-lowering supplements: Monitor (theoretical). Additive glucose lowering, with hypoglycemia risk mainly when combined with diabetes drugs.
  • Fish oil, glucomannan and other satiety or triglyceride-lowering supplements: Monitor (theoretical). Additive triglyceride lowering (fish oil) or fullness (glucomannan, a fiber); generally a desired effect but may reduce food intake excessively.
  • Fasting protocols and very-low-calorie diets: Caution (theoretical). Additive appetite suppression may make energy and protein intake too low; tracking weight and strength mitigates this.

Populations who should avoid Oleoylethanolamide:

  • Pregnant or breastfeeding women (excluded from trials; no safety data) (Batacan et al., 2026)
  • Children and adolescents under 18 (trials enrolled adults aged 18–65) (Batacan et al., 2026)
  • Underweight adults with a body mass index below 18.5 kg/m², the lower enrollment limit of a recent OEA trial (NCT07412730)
  • People with current or past eating disorders, such as anorexia nervosa
  • Frail older adults with unintended weight loss or sarcopenia (age-related loss of muscle mass and strength)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Start at the lowest studied dose: Starting with 125 mg/day, the dose used in the Qazvin trials (Pouryousefi et al., 2022), for 1–2 weeks before moving to 250 mg/day limits digestive upset.
  • Dosing with meals: Taking capsules with food, as in the veterans’ trial (Abdullah et al., 2026), may reduce digestive discomfort.
  • Weight tracking in lean or older users: Weekly weighing, with a pause if unintended loss exceeds about 5% of body weight, guards against excess appetite loss and muscle loss.
  • Protein protection: Keeping protein near 1.2 g/kg body weight per day while appetite is lower limits muscle loss.
  • Glucose checks with diabetes drugs: Fasting glucose checks several times weekly for the first 2–4 weeks, when combined with glucose-lowering drugs, detect hypoglycemia early.
  • Courses limited to tested durations: 8–15-week courses, the range studied in trials, followed by reassessment against baseline labs, limit exposure to unknown long-term risks.
  • Kidney and liver labs: Creatinine and liver enzymes at baseline and after 8–12 weeks detect possible fibrate-like or liver effects.
  • No unmonitored stacking of appetite suppressants: Combining OEA with GLP-1 drugs or extended fasting only under monitoring prevents excessive appetite and protein loss.
  • Verified products: Products with a certificate of analysis stating OEA content reduce the risk of underdosing or contamination.

Therapeutic Protocol

Each dose below is cited to its source; other parameters without a citation (timing, titration, cycling) reflect common practice.

  • Standard research regimen: 125 mg twice daily (250 mg/day) for 8–12 weeks, used by the Tabriz group in obesity and fatty liver (Laleh et al., 2018; Tutunchi et al., 2020).
  • Lower-dose regimen: 125 mg once daily for 8 weeks, used by the Qazvin group in prediabetes and polycystic ovary syndrome (Pouryousefi et al., 2022; Shivyari et al., 2024).
  • Higher-dose regimen: 200 mg twice daily (400 mg/day) with food for 10–15 weeks in the veterans’ fatigue trial (Abdullah et al., 2026).
  • Enhanced-absorption formulation: TRPTI, Gencor’s dispersible OEA, at 150 mg twice daily (at least 250 mg/day OEA) for 12 weeks (Batacan et al., 2026).
  • Fasting-mimetic combination: Mimio (spermidine, nicotinamide, palmitoylethanolamide and OEA), developed by Mimio Health after UC Davis fasting research (Rhodes et al., 2023), taken before the first meal daily (Grant et al., 2026).
  • Food-first alternative: Meals rich in oleic acid (olive oil, high-oleic sunflower oil) raised blood OEA and lowered later energy intake in a small crossover study by a Naples group (Mennella et al., 2015).
  • Time of day: Doses are commonly taken 15–30 minutes before the largest meals, typically morning and evening, to align with meal-related fullness signaling.
  • Half-life: Human half-life is unreported; OEA is rapidly degraded by FAAH and NAAA (Rahman et al., 2014), and blood levels rose within hours of a combination dose (Rhodes et al., 2024) and with repeated dosing (Abdullah et al., 2026).
  • Single versus split dose: Most trials split the daily dose into two, which fits its short, meal-linked action.
  • Genetic polymorphisms: FAAH rs324420 A-allele carriers have higher blood OEA (Pu et al., 2016); no study has adjusted dose by genotype.
  • Sex: No sex-specific dosing exists; inflammation-marker effects were seen mainly in female-only trials at 125 mg/day (Bahari et al., 2025).
  • Age: Trials enrolled adults up to about 70; for older adults, starting at 125 mg/day with weight and appetite tracking is common practice.
  • Baseline biomarkers: Weight and glucose effects were larger in people with obesity and at doses of 250 mg/day or more (Bahari et al., 2025).
  • Pre-existing conditions: Positive trials enrolled people with obesity, fatty liver, prediabetes or polycystic ovary syndrome; response in metabolically healthy adults is less certain (Ostadrahimi et al., 2024).

Discontinuation & Cycling

  • Short-term versus lifelong: OEA has been studied only in courses of up to 15 weeks; lifelong use has no supporting data.
  • Withdrawal effects: No withdrawal or rebound effects have been reported after stopping OEA in trials.
  • Tapering: No taper is needed, given no withdrawal effects and short action; stopping at once is common practice.
  • Cycling: No study has tested cycling; some users alternate 8–12-week courses with breaks, matching trial durations, without evidence that this preserves effect.
  • Reassessment after a course: Comparing weight, appetite and fasting glucose with baseline after 8–12 weeks shows whether continuing is worthwhile.

Sourcing and Quality

  • Forms available: Pure OEA capsules or powder (RiduZone capsules contain about 90% OEA (NCT04614233)), dispersible formulations such as TRPTI, and combination products such as Mimio.
  • What to look for: Stated milligrams of OEA per capsule, a batch certificate of analysis, manufacture under good manufacturing practice (GMP, a quality-control standard), and, where available, third-party testing for purity and contaminants.
  • Third-party certification: Independent certification (such as NSF International or U.S. Pharmacopeia seals) is uncommon for OEA products; a manufacturer certificate of analysis is the usual quality evidence.
  • Name confusion: “PEA” can mean palmitoylethanolamide or phenylethylamine (a stimulant); full ingredient names distinguish them on combination products.
  • Reputable sources: Products used in published trials include RiduZone (NutriForward), TRPTI (Gencor) and Mimio (Mimio Health); Designs for Health also sells an OEA powder.
  • Food sources: Foods such as cocoa, oatmeal and nuts contain under 2 µg/g of OEA (Batacan et al., 2026), far below supplemental doses.

Practical Considerations

  • Time to effect: Effects on food intake appeared after one dose (Briskey et al., 2026); changes in glucose, triglycerides and weight were measured after 8–12 weeks.
  • Common pitfalls: Expecting drug-like weight loss, relying on OEA without dietary change, buying products without stated OEA content, and combining it with GLP-1 drugs without tracking intake.
  • Regulatory status: In the US, OEA is sold as a dietary supplement, a category the US Food and Drug Administration (FDA) does not approve before sale (FDA); a trial report states that FDA acknowledged a new dietary ingredient notification in 2015 (Abdullah et al., 2026).
  • Evidence base: Most trials come from a few Iranian groups, and the newest were funded or run by the makers of the tested products (Gencor, Mimio Health).
  • Payer context: Insurers do not cover OEA, while costlier GLP-1 drugs are reimbursed in some systems; payers thus have no incentive to fund OEA research, a potential structural gap.
  • Cost and access: OEA is widely available online at typical supplement prices; it is not exceptionally expensive or hard to obtain.

Interaction with Foundational Habits

  • Sleep: No known direct effect (none); a 12-week trial found no change in sleep-quality scores (Batacan et al., 2026). A sleep and stress trial is under way (NCT07315516). No timing adjustment for sleep is known to be needed.
  • Nutrition: Potentiating with oleic-acid-rich diets, which raise the body’s own OEA (Mennella et al., 2015); sustained high-fat diets blunt OEA signaling in rodents (Igarashi et al., 2015). Olive oil and nuts fit this pattern; adequate protein matters as appetite falls.
  • Exercise: No human data (none established). PPAR-α-driven fat burning could theoretically complement endurance training, but appetite suppression may hinder recovery and muscle gain; dosing away from post-workout meals preserves hunger for refueling.
  • Stress management: Possibly beneficial (indirect): OEA improved mood in veterans with Gulf War Illness (Abdullah et al., 2026) and reduced stress-induced binge-like eating in rats (Romano et al., 2020); perceived-stress scores did not change in obese adults (Batacan et al., 2026).

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes reference points for the markers OEA is expected to change and for safety: fasting glucose, HbA1c (glycated hemoglobin, a three-month blood sugar average), fasting insulin, triglycerides, hs-CRP (high-sensitivity C-reactive protein, an inflammation marker), liver enzymes and creatinine, together with body weight, waist circumference and a short appetite diary. Ongoing monitoring follows a cadence of a repeat panel at 8–12 weeks, matching trial durations, then every 6 months if use continues. People taking glucose-lowering drugs add home glucose checks several times weekly during the first 2–4 weeks. Success means a meaningful fall in fasting glucose or triglycerides, less hunger and easier adherence to eating goals, with stable liver and kidney markers and no unwanted weight loss in lean users. Absence of change by 12 weeks suggests limited personal benefit.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 70–99 mg/dL (standard reference range) Expected to change; safety check with glucose-lowering drugs Fast 8–12 hours; pair with fasting insulin; pooled trials showed about 6 mg/dL reduction (Eslahi et al., 2025)
HbA1c 4.0–5.6% (standard reference range) Expected to change (unconfirmed in pooled trials) HbA1c = glycated hemoglobin; no pooled change (Bahari et al., 2025); no fasting needed; reflects about 3 months, so retest no sooner than 3 months
Fasting insulin / HOMA-IR Fasting insulin about 2.6–24.9 µIU/mL (standard reference range; varies by laboratory); HOMA-IR: no established target, track change from own baseline Expected to change HOMA-IR = homeostatic model assessment of insulin resistance, calculated from fasting glucose and insulin; draw with fasting glucose
Triglycerides Below 150 mg/dL (standard reference range) Expected to change Fast 9–12 hours; part of a standard lipid panel; avoid alcohol for 24 hours before
hs-CRP No established target; track change from own baseline Expected to change (inconsistent in trials) hs-CRP = high-sensitivity C-reactive protein, an inflammation marker; postpone testing during acute illness
ALT and AST ALT about 7–56 U/L; AST about 10–40 U/L (standard reference range; varies by laboratory) Safety check; also expected to fall in fatty liver ALT/AST = alanine and aspartate aminotransferase, liver enzymes; avoid strenuous exercise 48 hours before
Creatinine About 0.6–1.3 mg/dL (standard reference range; varies by sex and laboratory) Safety check (theoretical fibrate-like effect) Kidney filtration marker; avoid heavy meat meals and intense exercise the day before

Qualitative markers to track:

  • Hunger before meals and frequency of cravings
  • Portion sizes and ease of following eating goals
  • Energy levels and daytime fatigue
  • Mood and emotional well-being
  • Digestive comfort (bloating, nausea, stool changes)
  • Strength and exercise recovery, especially in older or lean users

Emerging Research

  • Alcohol use disorder in young adults: A phase 2 trial (NCT07503782) will give 42 adults aged 18–25 OEA 250 mg/day (as TRPTI) or placebo for 6 weeks; primary endpoints are inflammatory markers and bacterial toxin levels. Not yet recruiting. A positive result would extend OEA’s anti-inflammatory case to humans; a null result would weaken it.
  • Gut microbes and insulin sensitivity: A Gencor-sponsored recruiting trial (NCT07457723) compares TRPTI 300 mg/day with placebo in 90 healthy adults; the primary endpoint is imidazole propionate (a gut-bacterial product linked to insulin resistance). A positive result would support a microbiome route to glucose benefits; a null result would not.
  • Sleep and stress: A Gencor-sponsored recruiting trial (NCT07315516) tests 150 mg/day TRPTI against placebo, lavender oil and palmitoylethanolamide in 240 stressed adults for 8 weeks, measuring stress, anxiety and sleep quality. A positive result would add a stress benefit; a null result would keep OEA’s case metabolic.
  • Fullness-hormone response: A not-yet-recruiting crossover trial (NCT07850466) will test a single 150 mg TRPTI dose on GLP-1 in 20 overweight adults. A positive result would confirm the hormone mechanism under blinded, randomized conditions; a null result would question the earlier fixed-order finding.
  • Completed or stopped trials without results: A glucose-tolerance trial (NCT07412730) completed in April 2026 and an OEA–ginger–lavender trial (NCT07127445) completed in December 2025, both with no results posted; a Yale weight-maintenance trial (NCT04614233) was terminated in 2024 after its investigator changed institutions.
  • Fasting-mimetic combination: A combination of spermidine, nicotinamide, palmitoylethanolamide and OEA improved hunger ratings, LDL and fasting glucose versus placebo in 42 older adults (Grant et al., 2026); the trial was run with the manufacturer, Mimio Health, and cannot isolate OEA’s contribution.
  • Longevity in mammals: OEA extends worm lifespan (Folick et al., 2015), but lowering related lipids also extended worm lifespan under diet restriction (Lucanic et al., 2011); no mammalian lifespan or healthspan study exists, and one could strengthen or weaken the longevity rationale.
  • Independent and longer trials: Pooled effects rest on short trials mostly from Iran, with publication bias in several outcomes (Bahari et al., 2025); a null Australian trial (Batacan et al., 2026) already tempers weight and triglyceride claims, and longer independent studies could confirm or overturn the glucose signal.

Conclusion

Oleoylethanolamide is a natural fat-derived signal that the gut makes after meals, telling the body it is full and encouraging it to burn fat. As a supplement, it has been tested only in small, short human studies, mostly in people with obesity, fatty liver or early blood sugar problems. The most consistent finding is a modest drop in fasting blood sugar, reported by two separate research groups, although not every study agreed. Less certain signals include reduced food intake, lower blood fats, less fatigue and better mood in one veterans’ study, and less menstrual pain in one study. Any weight loss appears small, and cholesterol does not seem to change. The appeal for longevity rests on worm and mouse studies rather than human data.

Safety looks reassuring for courses of up to about four months: side effects were mild and no more common than with placebo. Effects of longer use are unknown, and its appetite-lowering action may be unwelcome for lean or frail older adults.

The evidence base is thin. Most trials come from a few research groups in Iran, several papers report results from the same small groups of participants, and the newest trials were paid for by the companies that sell the tested products, which may favor positive findings. For health-focused adults, oleoylethanolamide is a plausible, low-risk add-on for appetite and blood sugar, with an uncertain size and duration of benefit.

Top - Benefits - Risks - Protocol